CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival

Blood

Volumn 113, Issue 4, 2009, Pages 963-972

  Landsman, Limor ^a   Liat, Bar On ^a   Zernecke, Alma ^b   Kim, Ki Wook ^a   Krauthgamer, Rita ^a   Shagdarsuren, Erdenechimeg ^b   Lira, Sergio A ^c   Weissman, Irving L ^d   Weber, Christian ^b   Jung, Steffen ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; CX3C CHEMOKINE; FRACTALKINE; LIGAND; PROTEIN BCL 2; CHEMOKINE RECEPTOR; CX3CR1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL CULTURE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FOAM CELL; GENETIC POLYMORPHISM; HOMEOSTASIS; HUMAN; HUMAN CELL; INFLAMMATION; MONOCYTE; MOUSE; NONHUMAN; PHAGOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FAMILY; PROTEIN INTERACTION; RISK FACTOR; STEADY STATE; TRANSGENE; WILD TYPE; ANIMAL; C57BL MOUSE; CYTOLOGY; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY;

ANIMALS; ATHEROSCLEROSIS; CELL SURVIVAL; HOMEOSTASIS; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; RECEPTORS, CHEMOKINE;

EID: 59649092443     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-170787     Document Type: Article

References (66)

1. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121-127.
2. Pan Y, Lloyd C, Zhou H, et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature. 1997;387:611-617.
3. Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385:640-644.
4. Harrison JK, Jiang Y, Chen S, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A. 1998;95: 10896-10901.
5. Lucas AD, Chadwick N, Warren BF, et al. The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells in vivo. Am J Pathol. 2001;158:855-866.
6. Muehlhoefer A, Saubermann LJ, Gu X, et al. Fractalkine is an epithelial and endothelial cellderived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. J Immunol. 2000;164:3368-3376.
7. Ludwig A, Berkhout T, Moores K, Groot P, Chapman G. Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNFalpha and is modulated by metalloproteinase activity. J Immunol. 2002;168:604-612.
8. Papadopoulos EJ, Sassetti C, Saeki H, et al. Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up-regulated upon dendritic cell maturation. Eur J Immunol. 1999;29:2551-2559.
9. Greaves DR, Hakkinen T, Lucas AD, et al. Linked chromosome 16q13 chemokines, macrophagederived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2001;21:923-929.
10. Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997;91:521-530.
11. Combadiere C, Salzwedel K, Smith ED, Tiffany HL, Berger EA, Murphy PM. Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem. 1998;273:23799- 23804.
12. Nishiyori A, Minami M, Ohtani Y, et al. Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia? FEBS Lett. 1998;429: 167-172.
13. Jung S, Aliberti J, Graemmel P, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000;20: 4106-4114.
14. Niess JH, Brand S, Gu X, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science. 2005;307:254-258.
15. Landsman L, Varol C, Jung S. Distinct differentiation potential of blood monocyte subsets in the lung. J Immunol. 2007;178:2000-2007.
16. Fong AM, Robinson LA, Steeber DA, et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med. 1998;188: 1413-1419.
17. Garton KJ, Gough PJ, Blobel CP, et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem. 2001;276: 37993-38001.
18. Hundhausen C, Misztela D, Berkhout TA, et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood. 2003;102:1186-1195.
19. Ludwig A, Weber C. Transmembrane chemokines: versatile 'special agents' in vascular inflammation. Thromb Haemost. 2007;97:694-703.
20. Chandrasekar B, Mummidi S, Perla RP, et al. Fractalkine (CX3CL1) stimulated by nuclear factor -B (NF--B)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem J. 2003; 373:547-558.
21. Boehme SA, Lio FM, Maciejewski-Lenoir D, Bacon KB, Conlon PJ. The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia. J Immunol. 2000;165:397-403.
22. Brand S, Sakaguchi T, Gu X, Colgan SP, Reinecker HC. Fractalkine-mediated signals regulate cell-survival and immune-modulatory responses in intestinal epithelial cells. Gastroenterology. 2002;122:166-177.
23. Davis CN, Harrison JK. Proline 326 in the C terminus of murine CX3CR1 prevents G-protein and phosphatidylinositol 3-kinase-dependent stimulation of Akt and extracellular signal-regulated kinase in Chinese hamster ovary cells. J Pharmacol Exp Ther. 2006;316:356-363.
24. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508-519.
25. Moatti D, Faure S, Fumeron F, et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood. 2001;97:1925-1928.
26. McDermott DH, Halcox JP, Schenke WH, et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res. 2001;89:401-407.
27. Combadiere C, Potteaux S, Gao JL, et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation. 2003;107:1009-1016.
28. Lesnik P, Haskell CA, Charo IF. Decreased atherosclerosis in CX3CR1-/-mice reveals a role for fractalkine in atherogenesis. J Clin Invest. 2003;111:333-340.
29. Teupser D, Pavlides S, Tan M, Gutierrez-Ramos JC, Kolbeck R, Breslow JL. Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc Natl Acad Sci U S A. 2004;101: 17795-17800.
30. Saederup N, Chan L, Lira SA, Charo IF. Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/-mice: evidence for independent chemokine functions in atherogenesis. Circulation. 2008;117:1642-1648.
31. Liu P, Yu YR, Spencer JA, et al. CX3CR1 deficiency impairs dendritic cell accumulation in arterial intima and reduces atherosclerotic burden. Arterioscler Thromb Vasc Biol. 2008;28:243-250.
32. van Furth R, Cohn ZA. The origin and kinetics of mononuclear phagocytes. J Exp Med. 1968;128: 415-435.
33. Varol C, Landsman L, Fogg DK, et al. Monocytes give rise to mucosal, but not splenic, conventional dendritic cells. J Exp Med. 2007;204:171-180.
34. Randolph GJ. Differentiation of phagocytic monocytes into lynph node dendritic cells in vivo. Immunity. 1999;11:753-761.
35. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003;19:71-82.
36. Whitelaw DM. Observations on human monocyte kinetics after pulse labeling. Cell Tissue Kinet. 1972;5:311-317.
37. van Furth R. Origin and turnover of monocytes and macrophages. Curr Top Pathol. 1989;79:125-150.
38. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5:953-964.
39. Ziegler-Heitbrock L. The CD14-CD16-blood monocytes: their role in infection and inflammation. J Leukoc Biol. 2007;81:584-592.
40. Palframan RT, Jung S, Cheng G, et al. Inflammatory chemokine transport and presentation in HEV: a remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues. J Exp Med. 2001;194:1361-1373.
41. Nahrendorf M, Swirski FK, Aikawa E, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007;204:3037-3047.
42. Auffray C, Fogg D, Garfa M, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007;317:666-670.
43. Jakubzick C, Tacke F, Ginhoux F, et al. Blood monocyte subsets differentially give rise to CD103-and CD103-pulmonary dendritic cell populations. J Immunol. 2008;180:3019-3027.
44. Ancuta P, Rao R, Moses A, et al. Fractalkine preferentially mediates arrest and migration of CD16-monocytes. J Exp Med. 2003;197:1701-1707.
45. Tacke F, Alvarez D, Kaplan TJ, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007;117:185-194.
46. Cook DN, Chen SC, Sullivan LM, et al. Generation and analysis of mice lacking the chemokine fractalkine. Mol Cell Biol. 2001;21:3159-3165.
47. Lagasse E, Weissman IL. Bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages. J Exp Med. 1994;179:1047-1052.
48. Braunersreuther V, Zernecke A, Arnaud C, et al. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2007;27:373-379.
49. Serbina NV, Pamer EG. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol. 2006;7:311-317.
50. Lordan S, O'Callaghan YC, O'Brien NM. Deathsignaling pathways in human myeloid cells by oxLDL and its cytotoxic components 7beta-hydroxycholesterol and cholesterol-5beta,6betaepoxide. J Biochem Mol Toxicol. 2007;21:362-372.
51. Garcia-Cruset S, Carpenter KL, Guardiola F, Mitchinson MJ. Oxysterols in cap and core of human advanced atherosclerotic lesions. Free Radic Res. 1999;30:341-350.
52. Plump AS, Smith JD, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71: 343-353.
53. Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science. 1995; 267:1034-1037.
54. Bobryshev YV. Monocyte recruitment and foam cell formation in atherosclerosis. Micron. 2006; 37:208-222.
55. Bernhagen J, Krohn R, Lue H, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007;13:587-596.
56. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol. 2005; 25:2255-2264.
57. Zeiffer U, Schober A, Lietz M, et al. Neointimal smooth muscle cells display a proinflammatory phenotype resulting in increased leukocyte recruitment mediated by P-selectin and chemokines. Circ Res. 2004;94:776-784.
58. Volger OL, Fledderus JO, Kisters N, et al. Distinctive expression of chemokines and transforming growth factor-beta signaling in human arterial endothelium during atherosclerosis. Am J Pathol. 2007;171:326-337.
59. Lagasse E, Weissman IL. Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice. Cell. 1997;89:1021-1031.
60. Tanaka T, Bai Z, Srinoulprasert Y, Yang BG, Hayasaka H, Miyasaka M. Chemokines in tumor progression and metastasis. Cancer Sci. 2005; 96:317-322.
61. Zhou Y, Larsen PH, Hao C, Yong VW. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem. 2002;277: 49481-49487.
62. Kawada K, Sonoshita M, Sakashita H, et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res. 2004;64:4010-4017.
63. Tyner JW, Uchida O, Kajiwara N, et al. CCL5- CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nat Med. 2005;11:1180-1187.
64. Zernecke A, Bidzhekov K, Ozuyaman B, et al. CD73/ecto-5--nucleotidase protects against vascular inflammation and neointima formation. Circulation. 2006;113:2120-2127.
65. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
66. Swirski FK, Libby P, Aikawa E, et al. Ly-6Chi monocytes dominate hypercholesterolemiaassociated monocytosis and give rise to macrophages in atheromata. J Clin Invest. 2007;117: 195-205.